Globus Medical Reports Preliminary Q4 Sales $657M, Up 6.6% YoY; FY24 Sales $2.52B, Up 60.6% YoY; Sees 2025 Revenue $2.66B-$2.69B Vs $2.67B Est.; Non-GAAP EPS $3.40-$3.50 Vs $3.42 Est.

Benzinga · Jan 8 16:34

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.

The Company established its full year 2025 revenue guidance range of $2.66 billion to $2.69 billion and fully diluted non-GAAP earnings per share range between $3.40 to $3.50.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Globus Medical Reports Preliminary Q4 Sales $657M, Up 6.6% YoY; FY24 Sales $2.52B, Up 60.6% YoY; Sees 2025 Revenue $2.66B-$2.69B Vs $2.67B Est.; Non-GAAP EPS $3.40-$3.50 Vs $3.42 Est.

Risk Disclaimer